Procter & Gamble Health Limited (PGHL)
Valuation Rating
Score: 14/100
Valuation Overview
| P/E Ratio | 36.546707 |
| P/B Ratio | 14.138566 |
| Dividend Yield | 306.0% |
| Current Price | ₹5199.5 |
| DCF Value | ₹1648.3476461252362 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹5199.5 |
| DCF Value | ₹1648.3476461252362 |
| Graham Value | ₹1778.3750000000002 |
| DDM Value | ₹2308.5714285714284 |
| Earnings Value | ₹3709.399746546797 |
| Average Value | ₹1984.6482477239988 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 26.2% |
| Revenue Growth | -0.1% |
| Market Cap | ₹8630.86 Cr |
Valuation Analysis Score: 14/100
Undervaluation Score: 14/100
Valuation Score: 10/30
Growth Score: 4/30
Intrinsic Value Score: 0/40
Growth Score: 4/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Excellent operating margins above 20%
- Moderate growth confidence score above 40%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹5,199.50
Operating Margins: 38.1%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 50.5%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-04-16 19:15:06